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L
ike the Halloween nor’easter of 1991, AB plasma
is currently facing a perfect storm of competing
forces that is exacerbating the availability of an
already limited resource. One force is AABB Stan-
dard 5.4.1.2, which becomes effective for all plasma and
whole blood collected after April 1, 2014.1,2 Although
TRALI reduction strategies have already been widely
implemented for group A, B, and O donors for several
years, they have generally not been applied to group AB
donors due to concerns of AB plasma availability. The risk-
benefit of exempting AB donors was recently reassessed in
the face of epidemiology studies examining the efficacy of
TRALI reduction strategies. In general, TRALI cases and
TRALI fatalities have decreased dramatically over the past
several years for most products with the striking exception
of AB plasma.2 In a recent 4-year retrospective study of
TRALI cases reported to the American Red Cross, the odds
of TRALI with AB plasma were 14.5-fold higher than that of
plasma from other blood types (26.3 vs. 1.8 cases per
million units).3 The application of Standard 5.4.1.2 to AB
donors is projected to decrease AB plasma availability by
27% to 33%, with AB donors making up only 2.6% of
active donors.2
The second storm battering the AB plasma supply is
the widespread adoption of massive transfusion protocols
(MTPs), which advocate early and aggressive plasma
resuscitation. In an informal poll of recent AABB annual
meeting attendees, 93% had MTPs with fixed plasma:RBC
ratios.4 Moreover, 73% maintain a thawed plasma inven-
tory with most hospitals providing only AB plasma to
patients without a current or historical ABO type. Because
many trauma patients require transfer to large regional
trauma centers, these patients are more likely to initially
receive AB plasma due to the absence of a historical ABO
type on file at the receiving facility.5 The direct conse-
quence is overutilization of AB plasma since most patients
will be group A, O, or B. In addition, the use of fixed
plasma:RBC ratios often leads to plasma overtransfusion.
In one study, 86% of transfused trauma patients did not
meet the definition of massive transfusion, averaging only
three RBC transfusions in the first 12 hours.6 Finally, the
need to maintain thawed AB plasma inventories increases
AB utilization and transfusion to non-AB patients, as
unused plasma is diverted to other patients to prevent
wastage.7 An analysis at Dartmouth determined that
maintenance of a thawed, 2-unit AB plasma inventory
would increase yearly AB utilization by at least 25%.8 This
estimate closely mirrors the overall increase in AB plasma
use nationwide, which has risen 27% since 2006.7
Several suggestions have been offered to minimize
the impact of Standard 5.4.1.2 on AB plasma supplies.
Among the most controversial proposals is the initial use
of prethawed group A plasma for emergency release in
trauma and other MTP patients.2,7 Proponents of the prac-
tice argue that most patients will be compatible with
group A plasma, based on the known distribution of ABO
types in the population. Moreover, anti-B titers are rela-
tively low in most group A donors, especially male-only
donors who should lack immune-stimulated anti-B.9-11
Secretors may have additional protection from hemolysis
due to the presence of B substance capable of adsorbing
anti-B from transfused plasma.11 As evidence, they point
to the rarity of hemolytic transfusion reactions due to
incompatible group A PLT transfusions.12 Finally, patients
requiring an emergent MTP “pack” are also receiving
several units of group O RBCs, which further decreases the
risk of hemolysis.
In this issue, Chhibber and colleagues13 describe their
5-year experience using prethawed group A plasma for
emergency release at the University of Massachusets. To
monitor the safety of the policy, patients receiving incom-
patible plasma were prospectively monitored for clinical
and laboratory signs of hemolysis. Between 2008 and
2013, a total of 358 patients required emergency release,
group A plasma, representing less than 1% of their emer-
gency room admissions (135,000 per year). As expected,
most patients (84%) were group A or group O and there-
fore ABO compatible with group A plasma. Group A
plasma was dispensed to 54 group B and AB patients;
however, only 23 (6%) patients actually received group
A–incompatible plasma. Most patients received less than
4 units of plasma including 10 patients who required
plasma for warfarin reversal with little or no group O RBC
support. Nearly half of patients (11/23, 48%) also received
group O RBCs, with nine of 11 receiving at least 4 units.
Only three patients, however, approached the definition of
massive transfusion, receiving between 8 and 12 units of
group O RBCs. There was no overt evidence of acute
hemolytic transfusion reactions although three patients
had weak positive posttransfusion DATs.
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Two other institutions have published their experi-
ence or analysis of prethawed group A plasma.5,8 Both
Mayo Clinic and Dartmouth serve as regional trauma
centers for a geographically large rural population. In the
first 3 years, Mayo dispensed group A plasma to 254
patients without an ABO type on file.5 Like the patients in
the study by Chhibber and coworkers, most patients
were group A or group O (86%) and therefore ABO com-
patible with the product. Only 35 patients (14%) received
incompatible plasma due to a group B or AB blood type
with no adverse events and no discernable increase in
morbidity. One interesting finding was that only 2.5% of
trauma patients actually received emergency plasma
transfusion. Likewise, Dartmouth found that only a small
percentage of trauma patients (1.2%) required emergent
transfusion with the majority typing as group A and
group O (79%).8 At this time, Dartmouth provides 4 units
of group A plasma as part of their initial trauma pack
with no reported hemolytic transfusion reactions. Mayo
estimates that the policy potentially decreased AB
plasma use by 97%.5
A weakness and strength of the Massachusetts and
Mayo data is the small number of patients that ultimately
received ABO-incompatible plasma over a combined
8-year period. Overall, only 58 patients in the two studies
were group B or AB and only 12 patients required massive
transfusion. On average, these patients received between
500 and 750 mL of incompatible plasma or less than 20%
of their expected total blood volume. In the study by
Chhibber and colleagues nearly half of patients could now
be treated with prothrombinase complex to reverse war-
farin, thereby avoiding plasma exposure completely.2,13
Although no hemolysis or other acute adverse events were
observed, the number of patients is too small to assess the
incidence of other adverse outcomes attributed to non-
identical PLT and plasma transfusions.14,15 Finally, Mayo
and Massachusetts wisely restricted the use of group A
plasma to adult patients and their experience cannot be
extrapolated to pediatric populations.
Another concern is the demographics of the trauma
populations. Mayo and Dartmouth serve predominantly
rural white populations and even the Worcester area is
77% white, with black persons comprising only 7% of the
population.16 Racial diversity causes concern for large
urban hospitals with an ethnically diverse patient popu-
lation and a higher percentage of group B patients. It is
hoped that more data may soon become available from
the recently closed PROPPR study (Pragmatic Random-
ized Optimal Platelet and Plasma Ratios).17 PROPPR is a
multi-institutional prospective study involving 11 aca-
demic centers across the United States, including two that
dispense group A plasma for emergency release. Finally,
the US military manual allows the use of group A plasma
in emergencies and could be an additional source of infor-
mation on safety and patient outcomes.18
Despite the paucity of published literature, a poll of
attendees at a recent AABB annual meeting showed that
23% already use non-AB plasma for emergency release
and more than 90% were considering prethawed group A
plasma for massive transfusion patients.4 Some centers
using group A plasma employed different approaches to
further minimize the risk of ABO-incompatible plasma
transfusion. The Detroit Medical Center provides a mix of
group AB and A plasma (two AB, two A: four group O
RBCs) in their initial MTP, followed by transition to type-
specific or group A plasma for subsequent MTP packs as
necessary (B. O’Malley, personal communication, 2013).
Other centers withhold group A plasma until several units
of group O RBCs are transfused. For example, the Univer-
sity of Texas at San Antonio does not provide group A
plasma until the patient has received 8 units of group O
RBCs.4
Other mitigation strategies include screening group A
plasma for low anti-B titers. Dartmouth currently screens
group A plasma and reserves units with titers less than 50
(97% of units) for their MTP patients.8 Mayo does not
prescreen their units but documented that 90% of units
had a titer less than 64.10 These data are consistent with
other data that also show relatively low anti-B titers
among group A donors,9,11,12 although hemolysis due to
high-titer anti-B has been reported with aggressive oral
probiotic use.19 Practically, plasma units need to be iden-
tified and readily available to minimize delays in dispens-
ing plasma, effectively limiting this approach to centers
that collect allogeneic blood and can test donor samples
during manufacturing. Testing of thawed plasma by trans-
fusion services is impractical due to current plasma bag
design and time limitations. Furthermore, ABO titers can
vary between testing facility, method, and reagents and
cannot accurately predict the risk of hemolysis.12,20 Testing
of apheresis PLTs shows a wide range of testing practices
and titer cutoffs between institutions.12
It may be several years before the wisdom of group A
plasma in ABO-incompatible adult trauma and massive
transfusion patients can be fully assessed and confirmed,
although the initial literature suggests its safety. Early pub-
lished studies have been hampered by small numbers and
slow accrual of group B and AB patients requiring emer-
gency plasma transfusion.5,13 It will take significantly
larger patient numbers to examine other clinical outcome
measures such as the risk of acute lung injury, infection,
and mortality. It is possible that group A plasma may result
in less morbidity than AB plasma based on recent studies
in trauma patients.5,15 Future studies will also need to
address whether there are volume thresholds for incom-
patible plasma transfusion and the impact on subsequent
transfusion support. In patients who were massively
transfused with group O whole blood, transfusion of type-
specific blood was withheld for a period of 2 weeks due to
the risk of hemolysis.21
EDITORIAL
1696 TRANSFUSION Volume 54, July 2014
CONFLICT OF INTEREST
The author has disclosed no conflicts of interest.
Laura Cooling, MD,MS
e-mail: lcooling@med.umich.edu
Department of Pathology
University of Michigan
Ann Arbor, MI
REFERENCES
1. Carson TH. Standards for blood banks and transfusion ser-
vices. 29th ed. Bethesda (MD): American Association of
Blood Banks; 2014.
2. American Association of Blood Banks. Association Bulletin
#14-02. TRALI risk mitigation for plasma and whole blood
for allogeneic transfusion. 2014 [cited 2014 May 8]. Avail-
able from: http://www.aabb.org/resources/publications/
bulletins/Documents/ab14-02.pdf
3. Eder AF, Dy B, Perez J, et al. The residual risk of
transfusion-related acute lung injury risk at the American
Red Cross (2008-2011): limitations of a predominantly
male-donor plasma mitigation strategy. Transfusion 2013;
53:1442-9.
4. Research in progress: use of potentially incompatible
group A thawed plasma in trauma patients. 2013 AABB
Annual Meeting, Denver, CO, October 13, 2013.
5. Zelinski MD, Johnson PM, Jenkins D, et al. Emergency use
of prethawed group A plasma in trauma patients. J Trauma
Acute Care Surg 2013;74:69-75.
6. Inaba K, Branco BC, Rhee P, et al. Impact of plasma trans-
fusion in trauma patients who do not require massive
transfusion. J Am Coll Surg 2010;210:957-65.
7. Yazer M, Eder AF, Land KJ. How we manage AB plasma
inventory in the blood center and transfusion service.
Transfusion 2013;53:1627-33.
8. Mehr CR, Gupta R, von Recklinghausen FM, et al. Balanc-
ing risk and benefit: maintenance of a thawed group A
plasma inventory for trauma patients requiring massive
transfusion. J Trauma Acute Care Surg 2013;74:1425-31.
9. Isaak EJ, Tchorz KM, Lang N, et al. Challenging dogma:
group A donors as “universal plasma” donors in massive
transfusion protocols. Immunohematology 2011;27:61-5.
10. Tauscher C, Bendix B, Jacob EK, et al. Transfusing A plasma
to trauma patients: should we worry about anti-B
[abstract]. Transfusion 2013;53S:192A.
11. Cooling LL, Downs TA, Butch SH, et al. Anti-A and anti-B
titers in pooled group O platelets are comparable to
apheresis platelets. Transfusion 2008;48:2106-13.
12. Cooling L. ABO and platelet transfusion therapy. Immuno-
hematology 2007;23:20-33.
13. Chhibber V, Green M, Vauthrin M, et al. Is group A plasma
suitable as the first option for emergency release transfu-
sion? Transfusion 2014;54:1751-5.
14. Shanwell A, Andersson TM, Rostgaard K, et al. Post-
transfusion mortality among recipients of ABO-compatible
but non-identical plasma. Vox Sang 2009;96:316-23.
15. Inaba K, Branco BC, Rhee P, et al. Impact of ABO-identical
vs ABO-compatible nonidentical plasma transfusion in
trauma patients. Arch Surg 2010;145:899-906.
16. Worcester Regional Research Bureau. Report 13-01.
Worcester’s demographic trends: 2010 census. February
2013 [cited 2014 Mar 28]. Available from: http://www
.wrrb.org
17. National Institute of Health. Pragmatic, Randomized opti-
mized platelet and plasma ratios. 2012. [cited 2014 Mar
30]. Available from: http://www.clinicaltrials.gov/ct2/
show/NCT01545232?term=PROPPR&rank=1
18. Office of The Surgeon General, Borden Institute. Chapter
33, Battlefield transfusions. In: Cubano MA, Lenhart MK,
editors. Emergency war surgery. 4th revision. Fort Sam
Houston (TX): Office of The Surgeon General, Borden
Institute; 2013. p. 467-88 [cited 2014 March 20]. Available
from: http://www.cs.amedd.army.mil/borden
19. Daniel-Johnson J, Leitman S, Klein H, et al. Probiotic-
associated high-titer anti-B in a group A platelet donor as a
cause of severe hemolytic transfusion reactions. Transfu-
sion 2009;49:1845-9.
20. Karafin MS, Blagg L, Tobian AA, et al. ABO antibody titers
are not predictive of hemolytic reactions due to plasma-
incompatible platelet transfusions. Transfusion 2012;52:
2087-93.
21. Berseus O, Boman K, Nessen S, et al. Risks of hemolysis
due to anti-A and anti-B caused by the transfusion of
blood or blood components containing ABO-incompatible
plasma. Transfusion 2013;53:114S-123S.
EDITORIAL
Volume 54, July 2014 TRANSFUSION 1697
